Heat shock protein 70-2 (HSP70-2) overexpression in breast cancer
Breast cancer is one of the leading cause of cancer-related deaths in women worldwide and increasing rapidly in developing countries. In the present study, we investigated the potential role and association of HSP70-2 with breast cancer. HSP70-2 expression was examined in 154 tumor and 103 adjacent...
Saved in:
Published in | Journal of Experimental & Clinical Cancer Research Vol. 35; no. 1; p. 150 |
---|---|
Main Authors | , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Springer Science and Business Media LLC
22.09.2016
BioMed Central Ltd BioMed Central |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Breast cancer is one of the leading cause of cancer-related deaths in women worldwide and increasing rapidly in developing countries. In the present study, we investigated the potential role and association of HSP70-2 with breast cancer.
HSP70-2 expression was examined in 154 tumor and 103 adjacent non-cancerous tissue (ANCT) specimens and breast cancer cell lines (MCF7, BT-474, SK-BR-3 and MDA-MB-231) by RT-PCR, quantitative-PCR, immunohistochemistry, Western blotting, flow cytometry and indirect immunofluorescence. Plasmid driven short hairpin RNA approach was employed to validate the role of HSP70-2 in cellular proliferation, senescence, migration, invasion and tumor growth. Further, we studied the effect of HSP70-2 protein ablation on signaling cascades involved in apoptosis, cell cycle and Epithelial-Mesenchymal-Transition both in culture as well as in-vivo human breast xenograft mouse model.
HSP70-2 expression was detected in majority of breast cancer patients (83 %) irrespective of various histotypes, stages and grades. HSP70-2 expression was also observed in all breast cancer cells (BT-474, MCF7, MDA-MB-231 and SK-BR-3) used in this study. Depletion of HSP70-2 in MDA-MB-231 and MCF7 cells resulted in a significant reduction in cellular growth, motility, onset of apoptosis, senescence, cell cycle arrest as well as reduction of tumor growth in the xenograft model. At molecular level, down-regulation of HSP70-2 resulted in reduced expression of cyclins, cyclin dependent kinases, anti-apoptotic molecules and mesenchymal markers and enhanced expression of CDK inhibitors, caspases, pro-apoptotic molecules and epithelial markers.
HSP70-2 is over expressed in breast cancer patients and was involved in malignant properties of breast cancer. This suggests HSP70-2 may be potential candidate molecule for development of better breast cancer treatment. |
---|---|
AbstractList | Background Breast cancer is one of the leading cause of cancer-related deaths in women worldwide and increasing rapidly in developing countries. In the present study, we investigated the potential role and association of HSP70-2 with breast cancer. Methods HSP70-2 expression was examined in 154 tumor and 103 adjacent non-cancerous tissue (ANCT) specimens and breast cancer cell lines (MCF7, BT-474, SK-BR-3 and MDA-MB-231) by RT-PCR, quantitative-PCR, immunohistochemistry, Western blotting, flow cytometry and indirect immunofluorescence. Plasmid driven short hairpin RNA approach was employed to validate the role of HSP70-2 in cellular proliferation, senescence, migration, invasion and tumor growth. Further, we studied the effect of HSP70-2 protein ablation on signaling cascades involved in apoptosis, cell cycle and Epithelial-Mesenchymal-Transition both in culture as well as in-vivo human breast xenograft mouse model. Results HSP70-2 expression was detected in majority of breast cancer patients (83 %) irrespective of various histotypes, stages and grades. HSP70-2 expression was also observed in all breast cancer cells (BT-474, MCF7, MDA-MB-231 and SK-BR-3) used in this study. Depletion of HSP70-2 in MDA-MB-231 and MCF7 cells resulted in a significant reduction in cellular growth, motility, onset of apoptosis, senescence, cell cycle arrest as well as reduction of tumor growth in the xenograft model. At molecular level, down-regulation of HSP70-2 resulted in reduced expression of cyclins, cyclin dependent kinases, anti-apoptotic molecules and mesenchymal markers and enhanced expression of CDK inhibitors, caspases, pro-apoptotic molecules and epithelial markers. Conclusions HSP70-2 is over expressed in breast cancer patients and was involved in malignant properties of breast cancer. This suggests HSP70-2 may be potential candidate molecule for development of better breast cancer treatment. Keywords: HSP70-2, Breast cancer, Gene silencing, Apoptosis, Tumor growth Breast cancer is one of the leading cause of cancer-related deaths in women worldwide and increasing rapidly in developing countries. In the present study, we investigated the potential role and association of HSP70-2 with breast cancer. HSP70-2 expression was examined in 154 tumor and 103 adjacent non-cancerous tissue (ANCT) specimens and breast cancer cell lines (MCF7, BT-474, SK-BR-3 and MDA-MB-231) by RT-PCR, quantitative-PCR, immunohistochemistry, Western blotting, flow cytometry and indirect immunofluorescence. Plasmid driven short hairpin RNA approach was employed to validate the role of HSP70-2 in cellular proliferation, senescence, migration, invasion and tumor growth. Further, we studied the effect of HSP70-2 protein ablation on signaling cascades involved in apoptosis, cell cycle and Epithelial-Mesenchymal-Transition both in culture as well as in-vivo human breast xenograft mouse model. HSP70-2 expression was detected in majority of breast cancer patients (83 %) irrespective of various histotypes, stages and grades. HSP70-2 expression was also observed in all breast cancer cells (BT-474, MCF7, MDA-MB-231 and SK-BR-3) used in this study. Depletion of HSP70-2 in MDA-MB-231 and MCF7 cells resulted in a significant reduction in cellular growth, motility, onset of apoptosis, senescence, cell cycle arrest as well as reduction of tumor growth in the xenograft model. At molecular level, down-regulation of HSP70-2 resulted in reduced expression of cyclins, cyclin dependent kinases, anti-apoptotic molecules and mesenchymal markers and enhanced expression of CDK inhibitors, caspases, pro-apoptotic molecules and epithelial markers. HSP70-2 is over expressed in breast cancer patients and was involved in malignant properties of breast cancer. This suggests HSP70-2 may be potential candidate molecule for development of better breast cancer treatment. BACKGROUNDBreast cancer is one of the leading cause of cancer-related deaths in women worldwide and increasing rapidly in developing countries. In the present study, we investigated the potential role and association of HSP70-2 with breast cancer.METHODSHSP70-2 expression was examined in 154 tumor and 103 adjacent non-cancerous tissue (ANCT) specimens and breast cancer cell lines (MCF7, BT-474, SK-BR-3 and MDA-MB-231) by RT-PCR, quantitative-PCR, immunohistochemistry, Western blotting, flow cytometry and indirect immunofluorescence. Plasmid driven short hairpin RNA approach was employed to validate the role of HSP70-2 in cellular proliferation, senescence, migration, invasion and tumor growth. Further, we studied the effect of HSP70-2 protein ablation on signaling cascades involved in apoptosis, cell cycle and Epithelial-Mesenchymal-Transition both in culture as well as in-vivo human breast xenograft mouse model.RESULTSHSP70-2 expression was detected in majority of breast cancer patients (83 %) irrespective of various histotypes, stages and grades. HSP70-2 expression was also observed in all breast cancer cells (BT-474, MCF7, MDA-MB-231 and SK-BR-3) used in this study. Depletion of HSP70-2 in MDA-MB-231 and MCF7 cells resulted in a significant reduction in cellular growth, motility, onset of apoptosis, senescence, cell cycle arrest as well as reduction of tumor growth in the xenograft model. At molecular level, down-regulation of HSP70-2 resulted in reduced expression of cyclins, cyclin dependent kinases, anti-apoptotic molecules and mesenchymal markers and enhanced expression of CDK inhibitors, caspases, pro-apoptotic molecules and epithelial markers.CONCLUSIONSHSP70-2 is over expressed in breast cancer patients and was involved in malignant properties of breast cancer. This suggests HSP70-2 may be potential candidate molecule for development of better breast cancer treatment. Background Breast cancer is one of the leading cause of cancer-related deaths in women worldwide and increasing rapidly in developing countries. In the present study, we investigated the potential role and association of HSP70-2 with breast cancer. Methods HSP70-2 expression was examined in 154 tumor and 103 adjacent non-cancerous tissue (ANCT) specimens and breast cancer cell lines (MCF7, BT-474, SK-BR-3 and MDA-MB-231) by RT-PCR, quantitative-PCR, immunohistochemistry, Western blotting, flow cytometry and indirect immunofluorescence. Plasmid driven short hairpin RNA approach was employed to validate the role of HSP70-2 in cellular proliferation, senescence, migration, invasion and tumor growth. Further, we studied the effect of HSP70-2 protein ablation on signaling cascades involved in apoptosis, cell cycle and Epithelial-Mesenchymal-Transition both in culture as well as in-vivo human breast xenograft mouse model. Results HSP70-2 expression was detected in majority of breast cancer patients (83 %) irrespective of various histotypes, stages and grades. HSP70-2 expression was also observed in all breast cancer cells (BT-474, MCF7, MDA-MB-231 and SK-BR-3) used in this study. Depletion of HSP70-2 in MDA-MB-231 and MCF7 cells resulted in a significant reduction in cellular growth, motility, onset of apoptosis, senescence, cell cycle arrest as well as reduction of tumor growth in the xenograft model. At molecular level, down-regulation of HSP70-2 resulted in reduced expression of cyclins, cyclin dependent kinases, anti-apoptotic molecules and mesenchymal markers and enhanced expression of CDK inhibitors, caspases, pro-apoptotic molecules and epithelial markers. Conclusions HSP70-2 is over expressed in breast cancer patients and was involved in malignant properties of breast cancer. This suggests HSP70-2 may be potential candidate molecule for development of better breast cancer treatment. Breast cancer is one of the leading cause of cancer-related deaths in women worldwide and increasing rapidly in developing countries. In the present study, we investigated the potential role and association of HSP70-2 with breast cancer. HSP70-2 expression was examined in 154 tumor and 103 adjacent non-cancerous tissue (ANCT) specimens and breast cancer cell lines (MCF7, BT-474, SK-BR-3 and MDA-MB-231) by RT-PCR, quantitative-PCR, immunohistochemistry, Western blotting, flow cytometry and indirect immunofluorescence. Plasmid driven short hairpin RNA approach was employed to validate the role of HSP70-2 in cellular proliferation, senescence, migration, invasion and tumor growth. Further, we studied the effect of HSP70-2 protein ablation on signaling cascades involved in apoptosis, cell cycle and Epithelial-Mesenchymal-Transition both in culture as well as in-vivo human breast xenograft mouse model. HSP70-2 expression was detected in majority of breast cancer patients (83 %) irrespective of various histotypes, stages and grades. HSP70-2 expression was also observed in all breast cancer cells (BT-474, MCF7, MDA-MB-231 and SK-BR-3) used in this study. Depletion of HSP70-2 in MDA-MB-231 and MCF7 cells resulted in a significant reduction in cellular growth, motility, onset of apoptosis, senescence, cell cycle arrest as well as reduction of tumor growth in the xenograft model. At molecular level, down-regulation of HSP70-2 resulted in reduced expression of cyclins, cyclin dependent kinases, anti-apoptotic molecules and mesenchymal markers and enhanced expression of CDK inhibitors, caspases, pro-apoptotic molecules and epithelial markers. HSP70-2 is over expressed in breast cancer patients and was involved in malignant properties of breast cancer. This suggests HSP70-2 may be potential candidate molecule for development of better breast cancer treatment. |
ArticleNumber | 150 |
Audience | Academic |
Author | Sonika Devi Vitusha Suri Rajive Kumar Nirmala Jagadish Anil Suri Rukhsar Fatima Vikash Kumar T. C. Sadasukhi Abdul S. Ansari Nirmal K. Lohiya Namita Gupta Sumit Agarwal Vaishali Suri Anju Gupta |
Author_xml | – sequence: 1 givenname: Nirmala surname: Jagadish fullname: Jagadish, Nirmala – sequence: 2 givenname: Sumit surname: Agarwal fullname: Agarwal, Sumit – sequence: 3 givenname: Namita surname: Gupta fullname: Gupta, Namita – sequence: 4 givenname: Rukhsar surname: Fatima fullname: Fatima, Rukhsar – sequence: 5 givenname: Sonika surname: Devi fullname: Devi, Sonika – sequence: 6 givenname: Vikash surname: Kumar fullname: Kumar, Vikash – sequence: 7 givenname: Vaishali surname: Suri fullname: Suri, Vaishali – sequence: 8 givenname: Rajive surname: Kumar fullname: Kumar, Rajive – sequence: 9 givenname: Vitusha surname: Suri fullname: Suri, Vitusha – sequence: 10 givenname: Trilok Chand surname: Sadasukhi fullname: Sadasukhi, Trilok Chand – sequence: 11 givenname: Anju surname: Gupta fullname: Gupta, Anju – sequence: 12 givenname: Abdul S. surname: Ansari fullname: Ansari, Abdul S. – sequence: 13 givenname: Nirmal Kumar surname: Lohiya fullname: Lohiya, Nirmal Kumar – sequence: 14 givenname: Anil surname: Suri fullname: Suri, Anil |
BackLink | https://cir.nii.ac.jp/crid/1873116918034205568$$DView record in CiNii https://www.ncbi.nlm.nih.gov/pubmed/27658496$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kl1rFDEUhgep2A_9Ad7IgFLqxdSczOTrRliKukJBQb0OmcyZbupssk1miv77ZthWd4tIyAfJ875JzjnHxYEPHoviJZBzAMnfJahJwysCuTeUVepJcQSC8Uopzg921ofFcUrXhHBQoJ4Vh1RwJhvFj4rFEs1YplWwP8tNDCM6XwpS0fJs-e3rvHhbhluM-GsTMSUXfJmBNqJJY2mNtxifF097MyR8cT-fFD8-fvh-sawuv3z6fLG4rCynZKyw7jrLOlubnnactAQlBYCuFSKfGKu4Ia3oG-xaQE6kANI0CmtjGSAIW58U77e-m6ldY2fRj9EMehPd2sTfOhin90-8W-mrcKsZqZuGi2xwdm8Qw82EadRrlywOg_EYpqRBMiWo5JRn9PUj9DpM0efvZYoyKbli6i91ZQbUzvch32tnU71oBGFSCVln6vwfVG4drp3NCe1d3t8TnO4IVmiGcZXCMI05-mkffLUbkT-heMhuBsQWsDGkFLHX1o1m9slPcIMGouc60ts60rmO9FxHev4aPFI-mP9P82ar8c7li-YRpKgBuAKZc0AJY1zWd7Jd0CU |
CitedBy_id | crossref_primary_10_1186_s13048_018_0475_z crossref_primary_10_1002_mco2_161 crossref_primary_10_1016_j_prp_2022_154127 crossref_primary_10_1139_bcb_2018_0177 crossref_primary_10_1177_1533033818785274 crossref_primary_10_3390_cancers12102749 crossref_primary_10_3390_cells10123446 crossref_primary_10_1038_s41598_019_43556_1 crossref_primary_10_17826_cumj_435450 crossref_primary_10_3390_ijms19092603 crossref_primary_10_3390_cells9102332 crossref_primary_10_3390_ijms24087485 crossref_primary_10_3390_ijms21124296 crossref_primary_10_1002_mco2_70129 crossref_primary_10_2217_epi_2023_0154 crossref_primary_10_1007_s00216_019_02220_3 crossref_primary_10_1038_s41418_019_0400_z crossref_primary_10_1038_s41388_019_0978_0 crossref_primary_10_3390_cancers13061252 crossref_primary_10_1002_cbdv_202200746 crossref_primary_10_1371_journal_pone_0200619 crossref_primary_10_1007_s00383_017_4211_3 crossref_primary_10_1155_2022_6229444 crossref_primary_10_1016_j_tranon_2020_100754 crossref_primary_10_1016_j_tranon_2020_100776 crossref_primary_10_1021_acs_molpharmaceut_4c00140 crossref_primary_10_1590_1806_9282_20210495 crossref_primary_10_1016_j_identj_2024_10_008 crossref_primary_10_1158_2767_9764_CRC_24_0094 crossref_primary_10_2174_1389450120666181211111815 crossref_primary_10_3390_ijms23147792 crossref_primary_10_1186_s12885_021_08041_x crossref_primary_10_3389_fonc_2021_749673 crossref_primary_10_3390_cancers14030605 crossref_primary_10_3390_app11031175 crossref_primary_10_1016_j_molmed_2019_05_011 crossref_primary_10_1021_acsnano_8b03726 crossref_primary_10_3390_cells9010060 crossref_primary_10_1134_S1990519X23010066 crossref_primary_10_3390_molecules27207132 crossref_primary_10_3390_ijms25020876 crossref_primary_10_1002_1878_0261_12821 crossref_primary_10_52711_0974_360X_2022_00273 crossref_primary_10_1016_j_clbc_2020_11_005 crossref_primary_10_1016_j_ejcb_2017_09_003 crossref_primary_10_3390_cancers14174289 |
Cites_doi | 10.1007/s13277-014-2594-5 10.1016/j.bbrc.2008.03.040 10.1002/cncr.25218 10.2174/1381612821666141211154707 10.1038/cddis.2014.244 10.1101/gad.305405 10.2217/bmt.12.60 10.1016/j.ejca.2009.10.020 10.1242/dev.124.15.3007 10.3322/caac.21332 10.1371/journal.pone.0057095 10.1186/s13046-015-0258-y 10.1111/j.1524-4741.2007.00393.x 10.1038/nrm1835 10.1111/j.1582-4934.2009.00873.x 10.1158/1055-9965.EPI-08-0629 10.1073/pnas.1017909109 10.1158/2159-8290.CD-12-0429 10.1016/j.arcmed.2013.10.005 10.1038/nature13119 10.1016/S0140-6736(13)62224-2 10.1186/bcr3168 10.1002/path.3022 10.1016/j.tibs.2006.01.006 10.4137/CPath.S31563 10.1371/journal.pone.0081348 10.1016/j.cell.2011.02.013 |
ContentType | Journal Article |
Copyright | COPYRIGHT 2016 BioMed Central Ltd. Copyright BioMed Central 2016 The Author(s). 2016 |
Copyright_xml | – notice: COPYRIGHT 2016 BioMed Central Ltd. – notice: Copyright BioMed Central 2016 – notice: The Author(s). 2016 |
DBID | RYH AAYXX CITATION NPM 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM |
DOI | 10.1186/s13046-016-0425-9 |
DatabaseName | CiNii Complete CrossRef PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni Edition) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) Medical Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database PubMed |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1756-9966 |
EndPage | 150 |
ExternalDocumentID | PMC5034467 4203985351 A470589783 27658496 10_1186_s13046_016_0425_9 |
Genre | Journal Article |
GeographicLocations | India |
GeographicLocations_xml | – name: India |
GrantInformation_xml | – fundername: ; – fundername: ; grantid: BT/IN/UK/NII/2006; BT/PR/14549/MED/14/1291 |
GroupedDBID | --- 0R~ 29K 2WC 4.4 5GY 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML ABDBF ABUWG ACGFO ACGFS ADBBV ADRAZ ADUKV AENEX AFKRA AFPKN AHBYD AHMBA AHSBF AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AOIJS BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 D-I DIK DU5 E3Z EBD EBLON EBS EJD ESX F5P FYUFA GROUPED_DOAJ H13 HMCUK HYE IAO IEA IHR IHW INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV RYH SMD SOJ TR2 TUS UKHRP ~8M AAYXX CITATION NPM PMFND 3V. 7XB 8FK AZQEC DWQXO K9. PJZUB PKEHL PPXIY PQEST PQUKI PRINS 7X8 5PM |
ID | FETCH-LOGICAL-c620t-e3ddc5dc3af2d60b0e82111db773ddac96a0b7f4edb1e608710449e3ac51e17c3 |
IEDL.DBID | M48 |
ISSN | 1756-9966 0392-9078 |
IngestDate | Thu Aug 21 13:50:40 EDT 2025 Fri Jul 11 09:19:34 EDT 2025 Fri Jul 25 05:14:27 EDT 2025 Tue Jun 17 22:05:15 EDT 2025 Tue Jun 10 21:05:01 EDT 2025 Thu May 22 21:24:16 EDT 2025 Thu Apr 03 07:08:45 EDT 2025 Tue Jul 01 02:26:28 EDT 2025 Thu Apr 24 23:01:26 EDT 2025 Thu Jun 26 23:05:41 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | HSP70-2 Gene silencing Breast cancer Tumor growth Apoptosis |
Language | English |
License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c620t-e3ddc5dc3af2d60b0e82111db773ddac96a0b7f4edb1e608710449e3ac51e17c3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0001-5244-5069 0000-0002-5812-9283 |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s13046-016-0425-9 |
PMID | 27658496 |
PQID | 1825886959 |
PQPubID | 105475 |
PageCount | 1 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_5034467 proquest_miscellaneous_1859728626 proquest_journals_1825886959 gale_infotracmisc_A470589783 gale_infotracacademiconefile_A470589783 gale_healthsolutions_A470589783 pubmed_primary_27658496 crossref_citationtrail_10_1186_s13046_016_0425_9 crossref_primary_10_1186_s13046_016_0425_9 nii_cinii_1873116918034205568 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2016-09-22 |
PublicationDateYYYYMMDD | 2016-09-22 |
PublicationDate_xml | – month: 09 year: 2016 text: 2016-09-22 day: 22 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: London |
PublicationTitle | Journal of Experimental & Clinical Cancer Research |
PublicationTitleAlternate | J Exp Clin Cancer Res |
PublicationYear | 2016 |
Publisher | Springer Science and Business Media LLC BioMed Central Ltd BioMed Central |
Publisher_xml | – name: Springer Science and Business Media LLC – name: BioMed Central Ltd – name: BioMed Central |
References | O Straume (425_CR6) 2012; 109 B Shang (425_CR26) 2014; 5 CJ Dougherty (425_CR21) 2008; 370 Q Cheng (425_CR7) 2012; 14 P Yang (425_CR25) 2015; 21 J Tabernero (425_CR27) 2013; 3 M Garg (425_CR9) 2010; 46 GJ Lindeman (425_CR20) 2013; 2 P Vineis (425_CR4) 2014; 383 J Makki (425_CR2) 2015; 8 N Jagadish (425_CR14) 2015; 34 GH Williams (425_CR18) 2012; 226 M Rohde (425_CR8) 2005; 19 J Wang (425_CR23) 2009; 13 D Kanojia (425_CR13) 2013; 8 S Singh (425_CR11) 2014; 35 JP Thiery (425_CR24) 2006; 7 D Zhu (425_CR19) 1997; 124 X Chen (425_CR22) 2014; 508 D Hanahan (425_CR17) 2011; 144 S Saini (425_CR15) 2013; 8 D Kanojia (425_CR12) 2009; 18 SY Hou (425_CR16) 2014; 45 SK Calderwood (425_CR5) 2006; 31 R Siegel (425_CR1) 2016; 66 BJ Yoder (425_CR3) 2007; 13 M Garg (425_CR10) 2010; 116 25506890 - Curr Pharm Des. 2015;21(10):1292-300 26740749 - Clin Med Insights Pathol. 2015 Dec 21;8:23-31 24316396 - Arch Med Res. 2014 Jan;45(1):44-51 23358650 - Cancer Discov. 2013 Apr;3(4):406-17 26590805 - J Exp Clin Cancer Res. 2015 Nov 21;34:142 16493418 - Nat Rev Mol Cell Biol. 2006 Feb;7(2):131-42 24351322 - Lancet. 2014 Feb 8;383(9916):549-57 24349057 - PLoS One. 2013 Dec 09;8(12):e81348 21376230 - Cell. 2011 Mar 4;144(5):646-74 19190149 - Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):630-9 16483782 - Trends Biochem Sci. 2006 Mar;31(3):164-72 21990031 - J Pathol. 2012 Jan;226(2):352-64 24670641 - Nature. 2014 Apr 3;508(7494):103-7 15741319 - Genes Dev. 2005 Mar 1;19(5):570-82 9247342 - Development. 1997 Aug;124(15):3007-14 26742998 - CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30 20564126 - Cancer. 2010 Aug 15;116(16):3785-96 19914824 - Eur J Cancer. 2010 Jan;46(1):207-15 24901056 - Cell Death Dis. 2014 Jun 05;5:e1285 19674193 - J Cell Mol Med. 2009 Sep;13(9B):3888-97 18355444 - Biochem Biophys Res Commun. 2008 May 23;370(1):109-12 23451156 - PLoS One. 2013;8(2):e57095 22589302 - Proc Natl Acad Sci U S A. 2012 May 29;109(22):8699-704 25213699 - Tumour Biol. 2014 Dec;35(12):12695-706 22510516 - Breast Cancer Res. 2012 Apr 17;14(2):R62 17319859 - Breast J. 2007 Mar-Apr;13(2):172-9 |
References_xml | – volume: 35 start-page: 12695 year: 2014 ident: 425_CR11 publication-title: Tumor Biol doi: 10.1007/s13277-014-2594-5 – volume: 370 start-page: 109 year: 2008 ident: 425_CR21 publication-title: Biochem Biophys Res Commun doi: 10.1016/j.bbrc.2008.03.040 – volume: 116 start-page: 3785 year: 2010 ident: 425_CR10 publication-title: Cancer doi: 10.1002/cncr.25218 – volume: 21 start-page: 1292 year: 2015 ident: 425_CR25 publication-title: Curr Pharm Des doi: 10.2174/1381612821666141211154707 – volume: 5 start-page: e1285 year: 2014 ident: 425_CR26 publication-title: Cell Death Dis doi: 10.1038/cddis.2014.244 – volume: 19 start-page: 570 year: 2005 ident: 425_CR8 publication-title: Genes Dev doi: 10.1101/gad.305405 – volume: 2 start-page: 1 year: 2013 ident: 425_CR20 publication-title: Breast Cancer Manag doi: 10.2217/bmt.12.60 – volume: 46 start-page: 207 year: 2010 ident: 425_CR9 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2009.10.020 – volume: 124 start-page: 3007 year: 1997 ident: 425_CR19 publication-title: Development doi: 10.1242/dev.124.15.3007 – volume: 66 start-page: 7 year: 2016 ident: 425_CR1 publication-title: CA Cancer J Clin doi: 10.3322/caac.21332 – volume: 8 start-page: e57095 year: 2013 ident: 425_CR15 publication-title: PLoS ONE doi: 10.1371/journal.pone.0057095 – volume: 34 start-page: 142 year: 2015 ident: 425_CR14 publication-title: J Exp Clin Cancer Res doi: 10.1186/s13046-015-0258-y – volume: 13 start-page: 172 year: 2007 ident: 425_CR3 publication-title: Breast J doi: 10.1111/j.1524-4741.2007.00393.x – volume: 7 start-page: 131 year: 2006 ident: 425_CR24 publication-title: Nat Rev Mol Cell Biol doi: 10.1038/nrm1835 – volume: 13 start-page: 3888 year: 2009 ident: 425_CR23 publication-title: J Cell Mol Med doi: 10.1111/j.1582-4934.2009.00873.x – volume: 18 start-page: 630 year: 2009 ident: 425_CR12 publication-title: Cancer Epidemiol Biomarkers Prev doi: 10.1158/1055-9965.EPI-08-0629 – volume: 109 start-page: 8699 year: 2012 ident: 425_CR6 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1017909109 – volume: 3 start-page: 406 year: 2013 ident: 425_CR27 publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-12-0429 – volume: 45 start-page: 44 year: 2014 ident: 425_CR16 publication-title: Arch Med Res doi: 10.1016/j.arcmed.2013.10.005 – volume: 508 start-page: 103 year: 2014 ident: 425_CR22 publication-title: Nature doi: 10.1038/nature13119 – volume: 383 start-page: 549 year: 2014 ident: 425_CR4 publication-title: Lancet doi: 10.1016/S0140-6736(13)62224-2 – volume: 14 start-page: R62 year: 2012 ident: 425_CR7 publication-title: Breast Cancer Res doi: 10.1186/bcr3168 – volume: 226 start-page: 352 year: 2012 ident: 425_CR18 publication-title: J Pathol doi: 10.1002/path.3022 – volume: 31 start-page: 164 year: 2006 ident: 425_CR5 publication-title: Trends Biochem Sci doi: 10.1016/j.tibs.2006.01.006 – volume: 8 start-page: 23 year: 2015 ident: 425_CR2 publication-title: Clin Med Insights Pathol doi: 10.4137/CPath.S31563 – volume: 8 start-page: e81348 year: 2013 ident: 425_CR13 publication-title: PLoS One doi: 10.1371/journal.pone.0081348 – volume: 144 start-page: 646 year: 2011 ident: 425_CR17 publication-title: Cell doi: 10.1016/j.cell.2011.02.013 – reference: 26590805 - J Exp Clin Cancer Res. 2015 Nov 21;34:142 – reference: 25506890 - Curr Pharm Des. 2015;21(10):1292-300 – reference: 23451156 - PLoS One. 2013;8(2):e57095 – reference: 16493418 - Nat Rev Mol Cell Biol. 2006 Feb;7(2):131-42 – reference: 21990031 - J Pathol. 2012 Jan;226(2):352-64 – reference: 15741319 - Genes Dev. 2005 Mar 1;19(5):570-82 – reference: 26740749 - Clin Med Insights Pathol. 2015 Dec 21;8:23-31 – reference: 26742998 - CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30 – reference: 21376230 - Cell. 2011 Mar 4;144(5):646-74 – reference: 24351322 - Lancet. 2014 Feb 8;383(9916):549-57 – reference: 19914824 - Eur J Cancer. 2010 Jan;46(1):207-15 – reference: 24901056 - Cell Death Dis. 2014 Jun 05;5:e1285 – reference: 19674193 - J Cell Mol Med. 2009 Sep;13(9B):3888-97 – reference: 24316396 - Arch Med Res. 2014 Jan;45(1):44-51 – reference: 16483782 - Trends Biochem Sci. 2006 Mar;31(3):164-72 – reference: 20564126 - Cancer. 2010 Aug 15;116(16):3785-96 – reference: 18355444 - Biochem Biophys Res Commun. 2008 May 23;370(1):109-12 – reference: 22510516 - Breast Cancer Res. 2012 Apr 17;14(2):R62 – reference: 23358650 - Cancer Discov. 2013 Apr;3(4):406-17 – reference: 25213699 - Tumour Biol. 2014 Dec;35(12):12695-706 – reference: 24349057 - PLoS One. 2013 Dec 09;8(12):e81348 – reference: 24670641 - Nature. 2014 Apr 3;508(7494):103-7 – reference: 22589302 - Proc Natl Acad Sci U S A. 2012 May 29;109(22):8699-704 – reference: 17319859 - Breast J. 2007 Mar-Apr;13(2):172-9 – reference: 9247342 - Development. 1997 Aug;124(15):3007-14 – reference: 19190149 - Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):630-9 |
SSID | ssj0061919 ssib005900188 |
Score | 2.3817313 |
Snippet | Breast cancer is one of the leading cause of cancer-related deaths in women worldwide and increasing rapidly in developing countries. In the present study, we... Background Breast cancer is one of the leading cause of cancer-related deaths in women worldwide and increasing rapidly in developing countries. In the present... BACKGROUNDBreast cancer is one of the leading cause of cancer-related deaths in women worldwide and increasing rapidly in developing countries. In the present... |
SourceID | pubmedcentral proquest gale pubmed crossref nii |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 150 |
SubjectTerms | Analysis Breast cancer Development and progression Gene expression Genetic aspects Heat shock proteins Influence Stem cell research |
SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3ra9wwDDdrB2Nfxt67rt08GOwBprHj-PFpHGPlGHQMtsJ9M_Ej9KDkut4V9udXcnzZMkY_JASkJI4tyZKt_ETIW2vAK066ZbVKDZNRgkpF61mUUscQG97lcm-n39TiTH5dNsuy4LYpaZU7m5gNdVwHXCM_Bj-4MUbZxn66_MWwahTurpYSGnvkLkKXYUqXXo4BF8QGubAHzJCKoV9fdjW5UccbjluCEEjDAWLL7GReKtZ5r1-t_ud5_ptA-deMdPKQPCiuJJ0PY_-I3En9Y3LvtGyWPyHzBdhZujkHi0czHMOqp7pigr5f_PiOFx8o5m-m3yUXtqfA4DFJfUsDCsPVU3J28uXn5wUrFRNYUKLaslTHGJoY6rYTUVW-SgYCPB691kBpg1Vt5XUnU_Q8qQqCpUpKm-o2NDxxHepnZL9f9-kFoV75ZE2dOiutVJ1ovQwyiIh1IVqv6xmpdv3lQoETx6oWFy6HFUa5oYsdppBhFzs7Ix_HWy4HLI3bmF_jILjhd9BRD91caqyEqA204F3mQE2EN4e2_FAA7UdMqwnn4YQTNChMyEcw0PAVeOZG1xwRhAyCIyLUkIHbdyLgioZv3B95nJE3IxmfjFlrfVpfIw-EawJjxhl5PkjM-OFCo-9ngaInsjQyIO73lNKvzjP-d4MwjUof3N6sl-S-yOJtmRCHZH97dZ2OwIHa-ldZS24ACycR8w priority: 102 providerName: ProQuest |
Title | Heat shock protein 70-2 (HSP70-2) overexpression in breast cancer |
URI | https://cir.nii.ac.jp/crid/1873116918034205568 https://www.ncbi.nlm.nih.gov/pubmed/27658496 https://www.proquest.com/docview/1825886959 https://www.proquest.com/docview/1859728626 https://pubmed.ncbi.nlm.nih.gov/PMC5034467 |
Volume | 35 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3da9swEBdNC2MvY9_N1mYeDAYDbbIs6-NhjHa0hEHKKAuEvRjrwzRQ3C1JofvvdycrZh5h7MF68J1t6Xwn3Vnn3xHyxmjwioOqaSFDSYUXYFLeWOqFUN75Mm9iubfZhZzOxZdFudgj2_JWSYDrnaEd1pOar67f3_389QkM_mM0eC0_rHPc3oOgGA5QQWpG5AAWJoV2OhP9pgKECrHOBwOXgEJMqNMm585bDJapNFmP2uVylyP6dz7lHwvU-UPyIHmW2UmnCo_IXmgfk3uztHf-hKgpTLvZ-gomwCyiMyzbTDHKM0ziDHcpIbbN4LTFTPVN5lAjVk_J_Pzs2-cpTWUTqJOcbWgovHeld0XdcC-ZZUFDlJd7qxRQamdkzaxqRPA2D5JBxMSEMKGoXZmHXLniGdlvb9pwSDIrbTC6CI0RRsiG11Y44bjH4hC1VcWYsK2UKpcwxbG0xXUVYwstq06wFeaRoWArMybv-kt-dIAa_2J-haKvun9Ce2OsToTCcohKQw_eRg5UEHiyq9NfBdB_BLYacB4NOMGM3IB8DK8XRoFtrlWRI4yQRoRExBvScPn2xVdbLQU-XmotTQk9fd2T8c6YutaGm1vkgZiNY-A4Js87PekHzhU6gAYoaqBBPQOCfw8p7fIqgoCXiNUo1Yv_Hv9Lcp9H_TaU8yOyv1ndhmNwqDZ2QkZqoSbk4PTs4uvlJH6WmETTgfby9PtvspgbOQ |
linkProvider | Scholars Portal |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Zb9QwELbarQR9QdwstDRIIA7JauI4Ph4QWqDVlnZXFbRS30x8RF2pypbuVsCf4jcykwuCUN_6sKuVPEkce2Y833r8DSHPtYKoOMicpiJklHsOJuW1pZ5z6Z3PkqIq9zaZivEx_3SSnayQX-1ZGEyrbH1i5aj93OF_5NsQB2dKCZ3pd-ffKFaNwt3VtoRGrRb74ed3gGyLt3sfYX5fMLa7c_RhTJuqAtQJFi9pSL13mXdpXjAvYhsHBSAo8VZKaMmdFnlsZcGDt0kQMQCKmHMd0txlSUikS-G-q2SNpwBlBmTt_c708HPr-wGNVKVEYE0WFJFEs4-aKLG9SHATEqA7fMBQqO6thM16sFrOZv-Ldf9N2fxrDdy9TW41wWs0qrXtDlkJ5V1yY9Jsz98jozF49mhxCj42qgggZmUkY8qiV-Mvh_jjdYQZo-FHk31bRiBgMS1-GTlUv4v75PhaRvMBGZTzMjwikRU2aJWGQnPNRcFyyx13zGMlitzKdEjidryMawjMsY7GmamAjBKmHmKDSWs4xEYPyZvukvOaveMq4S2cBFMfQO0s34y4xNqLUkEPXlYSaPvwZJc3Rxig_8ii1ZPc6EmCzbpe8yZMNLwFfidKpglyFimkY0RyIwWXtypgGp-yMH8sYEiedc14Z8yTK8P8EmUAIDJEqUPysNaY7sWZxGhTQ4vs6VIngEzj_ZZydloxjmdIDCnk46u7tUVujo8mB-Zgb7r_hKyzStU1ZWyDDJYXl2ETwrelfdrYTES-XreZ_gYCllGY |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Heat+shock+protein+70-2+overexpression+in+breast+cancer&rft.jtitle=Journal+of+experimental+%26+clinical+cancer+research&rft.au=Jagadish%2C+Nirmala&rft.au=Agarwal%2C+Sumit&rft.au=Gupta%2C+Namita&rft.au=Fatima%2C+Rukhsar&rft.date=2016-09-22&rft.pub=BioMed+Central+Ltd&rft.issn=0392-9078&rft.volume=35&rft.issue=1&rft_id=info:doi/10.1186%2Fs13046-016-0425-9&rft.externalDocID=A470589783 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1756-9966&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1756-9966&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1756-9966&client=summon |